...
首页> 外文期刊>Lupus >Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome
【24h】

Late-onset biopsy-proven lupus nephritis without other associated autoimmune diseases: severity and long-term outcome

机译:晚期生物检查验证的狼疮肾炎没有其他相关的自身免疫疾病:严重程度和长期结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Purpose Lupus nephritis (LN) usually develops within the first years of systemic lupus erythematosus (SLE) onset and rarely after that. There are scarce studies comparing early- versus late-onset nephritis (before versus after five years of SLE diagnosis). The aim of this study was to compare the severity and long-term outcome (after 7 years) in these two, late-onset and early-onset, nephritis groups. Methods This study included 93 patients from rheumatology tertiary centers from Brazil and Italy, all of them with biopsy-proven LN with 7 years follow-up. Patients were divided in two groups: early-onset nephritis (n = 75) and late-onset nephritis (n = 18). Clinical and laboratorial data were obtained using a standardized electronic chart database protocol carried out at 1-6 months interval and established in 2000. Patients 50 years or with concomitant autoimmune diseases were excluded. Variables evaluated at the LN presentation were Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), creatinine, albumin, anti-DNA positivity and nephritis class. Variables evaluated at the long-term outcome (after 7 years) were Systemic Lupus International Collaborating Clinics Damage Index (SDI), creatinine, dialysis and mortality. Results The average time of LN presentation was 10.94 +/- 3.73 years for the late-onset and 1.20 +/- 1.60 years for the early-onset group. Their similar nephritis duration (12.44 +/- 3.2 versus 13.28 +/- 4.03 years, p = 0.41) and comparable mean ages (49.17 +/- 9.9 versus 44.11 +/- 10.8 years old, p = 0.06) allow a more accurate comparison. Regarding severity, late-onset was similar to early-onset group: SLEDAI (8 (range: 6-22) versus 12 (range: 2-24), p = 0.47), creatinine (1.36 +/- 0.94 versus 1.36 +/- 1.13 mg/dl, p = 0.99); albumin (2.84 +/- 0.65 versus 2.59 +/- 0.84 mg/dl, p = 0.30); proteinuria (3.77 +/- 2.18 versus 5.01 +/- 4.51 g/vol, p = 0.26); proliferative nephritis (44% (n = 8) versus 60% (n = 45), p = 0.23). There was also no difference in the long-term outcomes between groups: SDI (1 (range: 0-5) versus 0.5 (range: 0-5), p = 0.27); creatinine (2.04 +/- 2.38 versus 1.69 +/- 2.26 mg/dl, p = 0.56); dialysis (22% (n = 4) versus 13% (n = 10), p = 0.46) and mortality (0% (n = 0) versus 12% (n = 9), p = 0.19). Conclusion This study provides novel evidence of comparable long-term outcomes between late-onset and early-onset nephritis, which is most likely explained by the observation that at presentation, the clinical, laboratorial and histological features of late-onset and early-onset nephritis are similar. This suggests that there should be no distinct treatment targets and therapeutic interventions for the late- and early-onset groups.
机译:背景/目的狼疮肾炎(LN)通常在系统性红斑狼疮(SLE)发病的第一年内发展,很少在此之后。缺乏研究的早期肾炎(在SLE诊断五年后与之前的比较)进行比较。本研究的目的是在这两种,晚期发病和早期发作,肾炎群中比较严重程度和长期结果(7岁以后)。方法本研究包括来自巴西和意大利的动力学三级中心93名患者,所有这些患者都有活组织检查证明的LN与GT; 7年随访。患者分为两组:早起肾炎(n = 75)和晚期肾炎(n = 18)。使用标准化的电子图表数据库协议获得临床和实验室数据,并在2000年在2000年成立。患者> 50岁或伴随的自身免疫疾病被排除在外。在LN介绍时评估的变量是全身性狼疮红斑病活动指数(SLEDAI),肌酐,白蛋白,抗DNA阳性和肾炎类。在长期结果(7年后)评估的变量是全身性狼疮国际合作诊所损伤指数(SDI),肌酐,透析和死亡率。结果LN展示的平均时间为10.94 +/- 3.73岁,为早盘集团的晚期和1.20 +/- 1.60岁。它们类似的肾炎持续时间(12.44 +/- 3.2与13.28 +/- 4.03岁,P = 0.41)和可比平均年龄(49.17 +/- 9.9与44.11 +/- 10.8岁,P = 0.06)允许更准确的比较。关于严重程度,晚期开始与早期开始组:SLEDAI(8(范围:6-22)对12(范围:2-24),p = 0.47),肌酐(1.36 +/- 0.94与1.36 + / - 1.13 mg / dl,p = 0.99);白蛋白(2.84 +/- 0.65对2.59 +/- 0.84 mg / dl,p = 0.30);蛋白尿(3.77 +/- 2.18与5.01 +/- 4.51 g / vol,p = 0.26);增殖性肾炎(44%(n = 8)与60%(n = 45),p = 0.23)。组之间的长期结果也没有差异:SDI(1(范围:0-5)与0.5(范围:0-5),P = 0.27);肌酐(2.04 +/- 2.38对1.69 +/- 2.26 mg / dl,p = 0.56);透析(22%(n = 4)与13%(n = 10),p = 0.46)和死亡率(0%(n = 0)与12%(n = 9),p = 0.19)。结论本研究提供了晚期和早期发病性肾炎之间可比的长期结果的新迹象,这是最有可能通过观察到介绍,临床,实验室和后期肾炎的临床,实验室和组织学特征来解释是相似的。这表明患有早期和早期发作群体不应该有明显的治疗靶标和治疗干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号